FINHUB Insights

BSX · Q3 FY25 · Jul 1 – Sep 30, 2025

Boston Scientific Q3 FY25: where the revenue came from and where it went

Boston Scientific Q3 FY25: revenue $5.1B (+20% year over year). Net profit $0.8B. Largest cohort Electrophysiology EP $0.9B. The whole income statement as a sankey diagram from the SEC filing.

Period
Jul 1 – Sep 30, 2025
Reported
Nov 3, 2025 10-Q
Sankey diagram of Boston Scientific's income statement for Q3 FY25: revenue of $5.1 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$5.1B +20% year over year
Gross profit$3.5B 70% margin
Operating profit$1B 21% margin
Net profit$0.8B 15% margin

The numbers

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Sep 30, 2025).
ItemValueShare of revenueYear over year
Revenue 5.1 100% +20%
Electrophysiology EP 0.9 18% +64%
Global Endoscopy Endo Reporting… 0.7 14% +10%
Global Peripheral Interventions… 0.7 14% +17%
Interventional Cardiology… 0.7 14% +4%
Global Urology and Pelvic Health… 0.7 14% +28%
Cardiac Rhythm Management 0.6 12% +3%
Watchman 0.5 10% +35%
Global Neuromodulation Nm… 0.3 6% +9%
Cost of revenue−1.529%
Gross profit3.570% margin+1pp
SG&A−1.734%−3pp
Other−0.815%+0pp
Operating profit121% margin+3pp
Tax−0.1
Interest & other costs−0.1
Net profit0.815%+4pp
Filing on EDGAR More quarters of BSX

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters